P2.28-03 Symptomatic vs. Asymptomatic SARS-CoV-2 Infection Rates in Lung Cancer: Longitudinal Nucleocapsid Antibody Analysis

The COVID-19 pandemic raised concerns about the risk of severe outcomes from SARS-CoV-2 infection in patients with lung cancer (LC), and it appears vaccination is effective at reducing rates of symptomatic and severe COVID-19 among this vulnerable population. Traditional disease surveillance measures may not reflect the true incidence as cases may be asymptomatic or mild. Thus, a knowledge gap is determining the actual SARS-CoV-2 infection rate in LC patients. Sero-surveillance to detect the presence of infection-specific antibodies to SARS-CoV-2, such as anti-nucleocapsid IgG (anti-N), represents a direct approach to filling this important knowledge gap in the care of LC patients.